DrugPatentWatch Database Preview
Sandoz Inc Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?
SANDOZ INC has one hundred and thirty-five approved drugs.
There are four US patents protecting SANDOZ INC drugs. There are fourteen tentative approvals on SANDOZ INC drugs.
There are twenty patent family members on SANDOZ INC drugs in eighteen countries and two hundred and fifteen supplementary protection certificates in fourteen countries.
Summary for Sandoz Inc
| International Patents: | 20 |
| US Patents: | 4 |
| Tradenames: | 109 |
| Ingredients: | 106 |
| NDAs: | 135 |
| Patent Litigation for Sandoz Inc: | See patent lawsuits for Sandoz Inc |
| PTAB Cases with Sandoz Inc as petitioner: | See PTAB cases with Sandoz Inc as petitioner |
Drugs and US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | OFLOXACIN | ofloxacin | SOLUTION/DROPS;OPHTHALMIC | 076231-001 | May 14, 2004 | DISCN | No | No | Start Trial | Start Trial | |||||
| Sandoz Inc | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | INJECTABLE;INJECTION | 201048-002 | Aug 10, 2012 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | AT | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Sandoz Inc | PHENYLEPHRINE HYDROCHLORIDE | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 208905-002 | Jan 31, 2019 | AP1 | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | ROPINIROLE HYDROCHLORIDE | ropinirole hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201047-005 | Jun 6, 2012 | AB | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,252,984 | Start Trial |
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | 5,196,404*PED | Start Trial |
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,311,708 | Start Trial |
| Sandoz Inc | TIMOLOL MALEATE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020963-002 | Oct 21, 1998 | 6,174,524*PED | Start Trial |
| Sandoz Inc | TIMOLOL MALEATE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020963-001 | Oct 21, 1998 | 6,174,524*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANDOZ INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | 2009-09-01 |
International Patents for Sandoz Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200004413 | Start Trial |
| Canada | 2505836 | Start Trial |
| European Patent Office | 1069913 | Start Trial |
| New Zealand | 506921 | Start Trial |
| Australia | 3194799 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sandoz Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0387077 | SPC/GB04/003 | United Kingdom | Start Trial | PRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721 |
| 2316456 | CA 2017 00062 | Denmark | Start Trial | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
| 1304992 | PA2013025,C1304992 | Lithuania | Start Trial | PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323 |
| 0509752 | 49/1999 | Austria | Start Trial | PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306 |
| 1746976 | CA 2017 00030 | Denmark | Start Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
